Results 71 to 80 of about 2,534,599 (334)

PYCR1 inhibition in bone marrow stromal cells enhances bortezomib sensitivity in multiple myeloma cells by altering their metabolism

Molecular Oncology, EarlyView.
This study investigated how PYCR1 inhibition in bone marrow stromal cells (BMSCs) indirectly affects multiple myeloma (MM) cell metabolism and viability. Culturing MM cells in conditioned medium from PYCR1‐silenced BMSCs impaired oxidative phosphorylation and increased sensitivity to bortezomib.
Inge Oudaert, Lauren van den Broecke, Osman Aksoy, Judith Lind, Sonia Vallet, Arne Van der Vreken, Gamze Ates, Ann Massie, Ken Maes, Kim De Veirman, Elke De Bruyne, Karin Vanderkerken, Klaus Podar, Eline Menu   +13 more
wiley   +1 more source

Monoclonal antibodies to the cells of a regenerating limb [PDF]

, 1985
Monoclonal antibodies were raised against differentiated cells, and blastemal cells from regenerating limbs of adult newts (Notophthalmus viridescens) and screened for specific staining by immunocytochemistry.
Brockes, Jeremy P., Kintner, Chris R.
core  

Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody

bioRxiv, 2020
The newly identified 2019 novel coronavirus (2019-nCoV) has caused more than 800 laboratory-confirmed human infections, including 25 deaths, posing a serious threat to human health. Currently, however, there is no specific antiviral treatment or vaccine.
Xiao-long Tian, Cheng Li, Ailing Huang, Shuai Xia, Sicong Lu, Zhènglì Shí, Lu Lu, Shibo Jiang, Zhenlin Yang, Yanling Wu, T. Ying   +10 more
semanticscholar   +1 more source

In vitro properties of patient serum predict clinical outcome after high dose rate brachytherapy of hepatocellular carcinoma

Molecular Oncology, EarlyView.
Following high dose rate brachytherapy (HDR‐BT) for hepatocellular carcinoma (HCC), patients were classified as responders and nonresponders. Post‐therapy serum induced increased BrdU incorporation and Cyclin E expression of Huh7 and HepG2 cells in nonresponders, but decreased levels in responders.
Lukas Salvermoser, Jan Niklas Schäfer, Shraga Nahum Goldberg, Philipp Maximilian Kazmierczak, Moritz Nikolaus Gröper, Philipp Franz Linden, Elif Öcal, Tanja Burkard, Stefanie Corradini, Najib Ben Khaled, Moritz Wildgruber, Max Seidensticker, Jens Ricke, Matthias Stechele, Marianna Alunni‐Fabbroni   +14 more
wiley   +1 more source

MONOCLONAL ANTIBODIES

Hematology, Transfusion and Cell Therapy
Obinutuzumab, an anti CD-20 monoclonal antibody, can be used in combination with venetoclax, ibrutinib or acalabrutinib in CLL patients with newly diagnosed or relaps patient's treatment indications. Another anti CD-20 monoclonal antibody, rituximab, has
Zekeriya Aksöz
doaj   +1 more source

The immunotherapy potential of agonistic anti-CD137 (4-1BB) monoclonal antibodies for malignancies and chronic viral diseases [PDF]

, 2006
Pharmacological intervention on the immune system to achieve more intense lymphocyte responses has potential application in tumour immunology and in the treatment of chronic viral diseases. Immunostimulating monoclonal antibodies are defined as a new
Alfaro, C. (Carlos), Arina, A. (Ainhoa), Arribillaga, L. (Laura), Azpilicueta, A. (Arantza), Bendandi, M. (Maurizio), Huarte, E. (Eduardo), Lasarte, J.J. (Juan José), Melero, I. (Ignacio), Murillo, O. (Oihana), Perez-Gracia, J.L. (Jose Luis), Prieto, J. (Jesús), Tirapu, I. (Íñigo)   +11 more
core  

ABCC6 is a basolateral plasma membrane protein [PDF]

, 2013
RATIONALE:: ABCC6 plays a crucial role in ectopic calcification; mutations of the gene cause pseudoxanthoma elasticum and general arterial calcification of infancy.
Apana, A., Brampton, C., Ilias, A., Le Saux, O., Martin, L., Monostory, K., Paku, S., Pomozi, V., Sarkadi, B., Szakacs, G., Szeri, F., Varadi, A.   +11 more
core   +3 more sources

Monoclonal antibodies targeting CD38 in hematological malignancies and beyond

Immunological Reviews, 2016
CD38 is a multifunctional cell surface protein that has receptor as well as enzyme functions. The protein is generally expressed at low levels on various hematological and solid tissues, while plasma cells express particularly high levels of CD38.
N. Donk, M. Janmaat, T. Mutis, J. J. Lammerts van Bueren, T. Ahmadi, A. Sasser, H. Lokhorst, P. Parren   +7 more
semanticscholar   +1 more source

Glycosylated LGALS3BP is highly secreted by bladder cancer cells and represents a novel urinary disease biomarker

Molecular Oncology, EarlyView.
Urinary LGALS3BP is elevated in bladder cancer patients compared to healthy controls as detected by the 1959 antibody–based ELISA. The antibody shows enhanced reactivity to the high‐mannose glycosylated variant secreted by cancer cells treated with kifunensine (KIF).
Asia Pece, Giulio Lovato, Ilaria Cela, Arianna Mercatelli, Benedetta Ferro, Jussi Nikkola, Sara Pagotto, Tommaso Grottola, Vincenzo De Laurenzi, Rossella Cicchetti, Antonio Marchetti, Luigi Schips, Rossano Lattanzio, Stefano Iacobelli, Emily Capone, Peter Black, Mads Daugaard, Michele Marchioni, Gianluca Sala   +18 more
wiley   +1 more source

Developments in therapy with monoclonal antibodies and related proteins

Clinical medicine (London), 2017
Monoclonal antibody therapeutics have been approved for over 30 targets and diseases, most commonly cancer. Antibodies have become the new backbone of the pharmaceutical industry, which previously relied on small molecules. Compared with small molecules,
H Michael Shepard, Gail Lewis Phillips, Christopher D Thanos, M. Feldmann   +3 more
semanticscholar   +1 more source